Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%

Journal of Glaucoma

Volumn 18, Issue 2, 2009, Pages 153-156

  Huang, Ping ^a   Zhong, Zheng ^a   Wu, Lingling ^a   Liu, Weihua ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Glaucoma; Iris; Travoprost

Indexed keywords

TRAVOPROST;

ADOLESCENT; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CHINESE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; EYE COLOR; EYE PHOTOGRAPHY; FEMALE; HUMAN; IRIS; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHINA; CLOPROSTENOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EYE COLOR; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; IRIS; IRIS DISEASES; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67651102559     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31817d2372     Document Type: Article

References (13)

1. Franks WA, Renard JP, Cunliffe IA, et al. A 6-week, doublemasked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 2006;28:332-339.
2. Otaka I, Kumagai K, Inagaki Y, et al. Simple and inexpensive software designed for the evaluation of color. Am J Ophthalmol. 2002;133:140-142. (Pubitemid 34076515)
3. Imesch PD, Wallow IH, Albert DM. The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol. 1997;41: 117-123.
4. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563-569.
5. Camras CB; United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147. (Pubitemid 26046170)
6. Netland PA, Landry T, Sullivan EK, et al; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
7. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. J Jpn Ophthalmol Soc. 2001;105:314-321.
8. Latanoprost-Induced Iris Pigmentation Study Group. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol. 2006;50:96-99.
9. Chou SY, Chou CK, Kuang TM, et al. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye. 2005;19:784-787.
10. Arranz-Marquez E, Teus MA. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. Ophthalmology. 2007;114:1255-1258. (Pubitemid 47001506)
11. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;S41:129-138. (Pubitemid 27154537)
12. Cohen JA, Gross RL, Cheetham JK, et al. Two-year doublemasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(suppl 1):S45-S52. (Pubitemid 38317486)
13. Stjernschantz JW, Albert DM, Hu DN, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(suppl 1):S162-S175. (Pubitemid 35232231)